SP1 and B-cell chronic lymphocytic leukemia: Our previous work showed that treatment of CLL cells with mithramycin, a drug that intercalates into G-C rich areas of DNA to inhibit SP1-mediated gene transcription29, 30, quantitatively reduces levels of PKCβII mRNA without affecting cell viability24.